Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT02496208 trial: what clinicians have said so far
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
- NCT02496208 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02496208 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02496208 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma
- Interventions
- Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Arms
- Part I (cabozantinib s-malate, nivolumab) · Experimental
- Part II (cabozantinib s-malate, nivolumab, ipilimumab) · Experimental
- Enrollment
- 152 (estimated)
- Primary outcomes
- Recommended phase II dose (Phase I)
- Incidence of adverse events (Phase I)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 22, 2015
- Primary completion
- Jul 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02496208 · updated Oct 15, 2026
Publications
linked from the registry- Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, Ley L, Cordes LM, Chandran E, Steinberg SM, Lee S, Lee MJ, Rastogi S, Sato N, Cao L, Banday AR, Boudjadi S, Merino MJ, Toubaji A, Akbulut D, Redd B, Bagheri H, Costello R, Gurram S, Agarwal PK, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Parnes HL, Gulley JL, Saraiya B, Pal SK, Quinn D, Stein MN, Lara PN, Bottaro DP, Mortazavi A. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024 Sep 1;42(25):3033-3046. doi: 10.1200/JCO.23.02233. Epub 2024 Jul 2. PubMed 38954785
- Girardi DM, Niglio SA, Mortazavi A, Nadal R, Lara P, Pal SK, Saraiya B, Cordes L, Ley L, Ortiz OS, Cadena J, Diaz C, Bagheri H, Redd B, Steinberg SM, Costello R, Chan KS, Lee MJ, Lee S, Yu Y, Gurram S, Chalfin HJ, Valera V, Figg WD, Merino M, Toubaji A, Streicher H, Wright JJ, Sharon E, Parnes HL, Ning YM, Bottaro DP, Cao L, Trepel JB, Apolo AB. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2022 Apr 1;28(7):1353-1362. doi: 10.1158/1078-0432.CCR-21-3726. PubMed 35031545
- Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN Jr, Saraiya B, Pal SK, Stein MN, Mortazavi A. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 Nov 1;38(31):3672-3684. doi: 10.1200/JCO.20.01652. Epub 2020 Sep 11. PubMed 32915679